Mohs Surgery OK for Most Skin Cancers

Share this content:
Mohs Surgery OK for Most Skin Cancers
Mohs Surgery OK for Most Skin Cancers

(HealthDay News) -- Application of recently published appropriate-use criteria suggests Mohs micrographic surgery (MMS) can be used in nearly three-quarters of skin cancers, according to a study published in the July issue of the Journal of the American Academy of Dermatology.

Adam B. Blechman, MD, from the University of Virginia Health System in Charlottesville, and colleagues retrospectively identified all biopsy-proven skin cancers, excluding invasive melanoma, treated over an 8-month period using medical records (1,059 skin cancers). Use of MMS was classified as appropriate, inappropriate, or uncertain based on the appropriate-use criteria.

RELATED: Skin Cancer Resource Center

The researchers found that MMS was appropriate in 72.0% of cases, inappropriate in 20.4%, and uncertain in 7.6%. Just over half of skin cancers (59.3%) occurred in the following areas: head, neck, hands, feet, ankles, genitalia, nipples/areola, and pretibial surface.

"Using recently published appropriate-use criteria, 72.0% of skin cancers at this institution were appropriate for MMS," the researchers wrote.


  1. Blechman AB, Patterson JW, Russell MA. Application of Mohs micrographic surgery appropriate-use criteria to skin cancers at a university health system. J Am Acad Dermatol. 2014;71(1):29-35.

Related Resources

Related Slideshows

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs